Significance of Findings in RESPONSE Trial in Polycythemia Vera
Jean-Jaques Kiladjian, MD, PhD, discusses how the results from the RESPONSE trial impact patients with polycythemia vera.
Jean-Jaques Kiladjian, MD, PhD, professor of clinical pharmacology at Paris Diderot University, discusses how the results from the RESPONSE trial impact patients with polycythemia vera (PV).
For patients with PV who are resistant to hydroxyurea, their outcomes have generally been very poor with a reduced life expectancy and high risk of vascular complications, according to Kiladjian. Ruxolitinib (Jakafi) treatment has given these patients an opportunity for treatment with good efficacy and safety.
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
